Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 20 2022 - 4:01PM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology
company focused on the development of next generation nucleic acid
therapies targeting RNA to address both genetic and non-genetic
neurological disorders and hair loss disorders, today announced
that on July 19, 2022, it received a letter from the Office of
General Counsel of The Nasdaq Stock Market LLC informing it that
Nasdaq has confirmed that the Company has regained compliance with
the $1.00 per share minimum bid price requirement pursuant to
Nasdaq Listing Rule 5450(a)(1) and that the Company is in
compliance with all applicable listing standards. Accordingly, the
scheduled hearing before the Nasdaq Hearings Panel has been
cancelled and the Company’s Common Stock will continue to be listed
and traded on The Nasdaq Capital Market.
About Exicure
Exicure, Inc. is an early-stage biotechnology company developing
nucleic acid therapies targeting ribonucleic acid against validated
targets to neurological disorders and hair loss. The team includes
a diverse scientific group with expertise in nucleic acid
chemistry, drug development and neuroscience. Headquartered in
Chicago, Illinois, the Company conducts its discovery and
development efforts in-house with a dedicated 30,000 square foot
facility, including rapid and automated high throughput nucleic
acid synthesis and screening. For further information, see
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220720005754/en/
Media: Karen Sharma MacDougall 781-235-3060
ksharma@macdougall.bio
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024